Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 8.26 and traded as low as GBX 6.55. Shield Therapeutics shares last traded at GBX 6.60, with a volume of 3,824,224 shares traded.
Shield Therapeutics Trading Down 2.0%
The company has a debt-to-equity ratio of -199.87, a current ratio of 0.90 and a quick ratio of 2.16. The stock’s 50-day moving average is GBX 8.18 and its two-hundred day moving average is GBX 9.18. The stock has a market cap of £69.61 million, a P/E ratio of -3.26 and a beta of 1.88.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
